Search research articles
Contact Us
Filters
Showing results (121-130 of 133) with videos related to
Page
of 14
Sort By:
The Lancet. Oncology
|
July 9, 2017
Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial
Paul D Brown, Karla V Ballman, Jane H Cerhan, et al.
Neuro-Oncology
|
October 11, 2017
Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02
Evanthia Galanis, S Keith Anderson, C Ryan Miller, et al.
International Journal of Radiation Oncology, Biology, Physics
|
September 24, 2017
Stereotactic Radiosurgery With or Without Whole-Brain Radiation Therapy for Limited Brain Metastases: A Secondary Analysis of the North Central Cancer Treatment Group N0574 (Alliance) Randomized Controlled Trial
Thomas M Churilla, Karla V Ballman, Paul D Brown, et al.
International Journal of Radiation Oncology, Biology, Physics
|
October 27, 2019
Optimizing Whole Brain Radiation Therapy Dose and Fractionation: Results From a Prospective Phase 3 Trial (NCCTG N107C [Alliance]/CEC.3)
Daniel M Trifiletti, Karla V Ballman, Paul D Brown, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 22, 2015
Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial
Edith A Perez, E Aubrey Thompson, Karla V Ballman, et al.
JAMA Oncology
|
October 20, 2022
Association of Long-term Outcomes With Stereotactic Radiosurgery vs Whole-Brain Radiotherapy for Resected Brain Metastasis: A Secondary Analysis of The N107C/CEC.3 (Alliance for Clinical Trials in Oncology/Canadian Cancer Trials Group) Randomized Clinical Trial
Joshua D Palmer, Brett G Klamer, Karla V Ballman, et al.
Plos One
|
November 14, 2013
An integrated model of the transcriptome of HER2-positive breast cancer
Krishna R Kalari, Brian M Necela, Xiaojia Tang, et al.
Neuro-Oncology
|
July 18, 2020
CODEL: phase III study of RT, RT + TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design
Kurt A Jaeckle, Karla V Ballman, Martin van den Bent, et al.
Nature Communications
|
January 12, 2024
Carcinoembryonic antigen-expressing oncolytic measles virus derivative in recurrent glioblastoma: a phase 1 trial
Evanthia Galanis, Katharine E Dooley, S Keith Anderson, et al.
JAMA Oncology
|
October 31, 2024
Efficacy of Adding Veliparib to Temozolomide for Patients With MGMT-Methylated Glioblastoma: A Randomized Clinical Trial
Jann N Sarkaria, Karla V Ballman, Sani H Kizilbash, et al.
Page
of 14
Search research articles
Search
Showing results (121-130 of 133) with videos related to
Sort By:
Page
of 14
The Lancet. Oncology
|
July 9, 2017
Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial
Paul D Brown, Karla V Ballman, Jane H Cerhan, et al.
Neuro-Oncology
|
October 11, 2017
Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02
Evanthia Galanis, S Keith Anderson, C Ryan Miller, et al.
International Journal of Radiation Oncology, Biology, Physics
|
September 24, 2017
Stereotactic Radiosurgery With or Without Whole-Brain Radiation Therapy for Limited Brain Metastases: A Secondary Analysis of the North Central Cancer Treatment Group N0574 (Alliance) Randomized Controlled Trial
Thomas M Churilla, Karla V Ballman, Paul D Brown, et al.
International Journal of Radiation Oncology, Biology, Physics
|
October 27, 2019
Optimizing Whole Brain Radiation Therapy Dose and Fractionation: Results From a Prospective Phase 3 Trial (NCCTG N107C [Alliance]/CEC.3)
Daniel M Trifiletti, Karla V Ballman, Paul D Brown, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 22, 2015
Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial
Edith A Perez, E Aubrey Thompson, Karla V Ballman, et al.
JAMA Oncology
|
October 20, 2022
Association of Long-term Outcomes With Stereotactic Radiosurgery vs Whole-Brain Radiotherapy for Resected Brain Metastasis: A Secondary Analysis of The N107C/CEC.3 (Alliance for Clinical Trials in Oncology/Canadian Cancer Trials Group) Randomized Clinical Trial
Joshua D Palmer, Brett G Klamer, Karla V Ballman, et al.
Plos One
|
November 14, 2013
An integrated model of the transcriptome of HER2-positive breast cancer
Krishna R Kalari, Brian M Necela, Xiaojia Tang, et al.
Neuro-Oncology
|
July 18, 2020
CODEL: phase III study of RT, RT + TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design
Kurt A Jaeckle, Karla V Ballman, Martin van den Bent, et al.
Nature Communications
|
January 12, 2024
Carcinoembryonic antigen-expressing oncolytic measles virus derivative in recurrent glioblastoma: a phase 1 trial
Evanthia Galanis, Katharine E Dooley, S Keith Anderson, et al.
JAMA Oncology
|
October 31, 2024
Efficacy of Adding Veliparib to Temozolomide for Patients With MGMT-Methylated Glioblastoma: A Randomized Clinical Trial
Jann N Sarkaria, Karla V Ballman, Sani H Kizilbash, et al.
Page
of 14